New insulin study aims to tame type 2 diabetes when pills fall short

NCT ID NCT04980027

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a long-acting insulin called glargine (brand name Toujeo) in 228 adults with type 2 diabetes whose blood sugar was still too high despite taking oral diabetes medications. The main goal was to see how safe the insulin was, including any low blood sugar episodes. Researchers also checked whether it helped lower blood sugar levels and improved patients' satisfaction with their treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: insulin glargine (Toujeo)
What this could lead to: If successful, this could confirm that starting insulin glargine is a safe and effective option for people with type 2 diabetes who need better blood sugar control.
What could go wrong: This is a single-arm, phase 4 study with no comparison group, so results are less definitive. Side effects like low blood sugar (hypoglycemia) are possible with insulin therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Investigational site Number 3560003

Jaipur, 302017, India
Investigational site Number 3560013

Nashik, 422002, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.